Revolution Medicines, Inc. Revenue
Revolution Medicines, Inc. (RVMD) reported Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-02-25
- Revolution Medicines, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $0.00.
- Revolution Medicines, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $0.00.
- Revolution Medicines, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Revolution Medicines, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $11.58M, a 67.27% decline from fiscal 2022.
- Revolution Medicines, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $35.38M, a 20.38% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $742.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $742.00K derived: sum of 3 quarters · filed 2026-02-25 | $742.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $742.00K derived: sum of 2 quarters · filed 2026-02-25 | $742.00K derived: sum of 3 quarters · filed 2026-02-25 | $4.57M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $742.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $742.00K derived: sum of 2 quarters · filed 2026-02-25 | $4.57M derived: sum of 3 quarters · filed 2026-02-25 | $11.58M 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $3.82M derived: sum of 2 quarters · filed 2024-11-06 | $10.84M 10-Q · filed 2024-11-06 | $26.17M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $3.82M 10-Q · filed 2024-08-07 | $10.84M 10-Q · filed 2024-08-07 | $26.17M derived: sum of 3 quarters · filed 2025-02-26 | $29.52M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $7.01M 10-Q · filed 2024-05-08 | $22.34M derived: sum of 2 quarters · filed 2025-02-26 | $25.70M derived: sum of 3 quarters · filed 2025-02-26 | $34.82M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $15.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $18.69M derived: sum of 2 quarters · filed 2025-02-26 | $27.80M derived: sum of 3 quarters · filed 2025-02-26 | $35.38M 10-K · filed 2025-02-26 |
| 2022-09-30 | $3.36M 10-Q · filed 2023-11-06 | $12.47M derived: sum of 2 quarters · filed 2023-11-06 | $20.05M 10-Q · filed 2023-11-06 | $29.51M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $9.12M 10-Q · filed 2023-08-08 | $16.69M 10-Q · filed 2023-08-08 | $26.15M derived: sum of 3 quarters · filed 2024-02-26 | $27.25M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $7.58M 10-Q · filed 2023-05-08 | $17.04M derived: sum of 2 quarters · filed 2024-02-26 | $18.14M derived: sum of 3 quarters · filed 2024-02-26 | $26.84M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $9.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $10.56M derived: sum of 2 quarters · filed 2024-02-26 | $19.26M derived: sum of 3 quarters · filed 2024-02-26 | $29.39M 10-K · filed 2024-02-26 |
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-07 | $9.80M derived: sum of 2 quarters · filed 2022-11-07 | $19.93M 10-Q · filed 2022-11-07 | $28.68M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $8.70M 10-Q · filed 2022-08-09 | $18.83M 10-Q · filed 2022-08-09 | $27.58M derived: sum of 3 quarters · filed 2022-08-09 | $40.24M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $10.13M 10-Q · filed 2022-05-09 | $18.88M derived: sum of 2 quarters · filed 2022-05-09 | $31.54M derived: sum of 3 quarters · filed 2022-05-09 | $41.57M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $8.75M 10-K · filed 2021-03-02 | $21.41M derived: sum of 2 quarters · filed 2021-11-10 | $31.44M derived: sum of 3 quarters · filed 2021-11-10 | $42.98M 10-K · filed 2023-02-27 |
| 2020-09-30 | $12.66M 10-Q · filed 2021-11-10 | $22.69M derived: sum of 2 quarters · filed 2021-11-10 | $34.23M 10-Q · filed 2021-11-10 | $46.32M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $10.03M 10-Q · filed 2021-08-11 | $21.57M 10-Q · filed 2021-08-11 | $33.66M derived: sum of 3 quarters · filed 2021-08-11 | $46.16M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $11.55M 10-Q · filed 2021-05-10 | $23.63M derived: sum of 2 quarters · filed 2021-05-10 | $36.14M derived: sum of 3 quarters · filed 2021-05-10 | $48.42M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $12.09M 10-K · filed 2021-03-02 | $24.59M derived: sum of 2 quarters · filed 2021-03-02 | $36.88M derived: sum of 3 quarters · filed 2021-03-02 | $50.04M 10-K · filed 2022-02-28 |
| 2019-09-30 | $12.51M 10-K · filed 2021-03-02 | $24.79M derived: sum of 2 quarters · filed 2021-03-02 | $37.95M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $12.28M 10-K · filed 2021-03-02 | $25.45M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $13.17M 10-K · filed 2021-03-02 | |||
| 2018-12-31 | $20.16M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |